OTSGC-A24
/ OncoTherapy
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 28, 2022
da VINci: Safety and efficacy of the OTSGC-A24 vaccine and nivolumab in metastatic gastric cancer
(ESMO 2022)
- P1 | "These results support further investigation in randomized studies. Translational studies are underway."
Clinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
April 08, 2019
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
(clinicaltrials.gov)
- P1; N=40; Recruiting; Sponsor: National University Hospital, Singapore; Not yet recruiting ➔ Recruiting
Enrollment open
1 to 2
Of
2
Go to page
1